The metabolic landscape of RAS-driven cancers from biology to therapy
Name
nihms-1684793.pdf
Description
Accepted version
Size
1.95 MB
Format
Unknown
Checksum (MD5)
bef519050d30ac350c6b8190968a861a
Author(s)
Mukhopadhyay, Suman
Vander Heiden, Matthew G
McCormick, Frank
Date Issued
March 2021
Journal
Nature Cancer
Publisher
Springer Science and Business Media LLC
Version
Author's final manuscript
Abstract
Our understanding of how the RAS protein family, and in particular mutant KRAS promote metabolic dysregulation in cancer cells has advanced significantly over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer, and elucidating the underlying mechanisms could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/S43018-021-00184-X
